Organic compounds
The invention relates to particular substituted deuterated heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D1/D2 receptor signaling systems, and/or the treatment of residual symptoms.
1. A compound of formula I,
in free or salt form; or
a compound of formula II,
in free or salt form; or
a compound of formula III,
in free or salt form.
2. The compound according to claim 1 , wherein said compound is in salt form.
3. The compound according to claim 2 , wherein the salt is a toluenesulfonic acid addition salt.
4. The compound according to claim 1 , wherein the compound is the compound of Formula II in free or salt form.
5. A pharmaceutical composition comprising a compound according to claim 1 , in free or pharmaceutically acceptable salt form, in combination or association with a pharmaceutically acceptable diluent or carrier.
6. A method for the treatment of a central nervous system disorder comprising administering to a patient in need thereof a therapeutically effective amount of the compound according to claim 1 , in free or pharmaceutically acceptable salt form, wherein said disorder is selected from obesity, anxiety, depression, refractory depression, major depressive disorder (MDD), psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, social phobias, agitation, agitation in dementia, agitation in autism, post-traumatic stress disorder, impulse control disorders, and intermittent explosive disorder;
disorders associated with dementia selected from the group consisting of agitation/irritation, aggressive/assaultive behavior, anger, physical or emotional outbursts, psychosis, depression, and sleep disorders;
delusional disorder, major depression with psychosis, bipolar disorder with psychotic symptoms, brief psychotic disorder, schizophreniform disorder, schizoaffective disorder, and psychosis caused by a medical condition or substance use.
7. The method according to claim 6 , wherein said disorder is selected from a group consisting of obesity, anxiety, depression, refractory depression, major depressive disorder (MDD), psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, social phobias, agitation, agitation in dementia, agitation in autism, post-traumatic stress disorder, impulse control disorders, and intermittent explosive disorder.
8. The method according to claim 6 , wherein said disorder is one or more disorders associated with dementia selected from the group consisting of agitation/irritation, aggressive/assaultive behavior, anger, physical or emotional outbursts, psychosis, depression, and sleep disorders.
9. The method according to claim 6 , wherein the central nervous system disorder is residual phase symptoms of psychosis selected from blunted affect, emotional withdrawal, poor rapport, passive or apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking; somatic concern, anxiety, guilt feelings, tension, mannerisms and posturing, depression, motor retardation, uncooperativeness, unusual thought content, disorientation, poor attention, lack of judgment and insight, disturbance of volition, poor impulse control, preoccupation and active social avoidance; cognitive impairment, and sleep disorders.
10. The method according to claim 6 , further comprising the administration of one or more other therapeutic agents.
11. The method according to claim 10 , wherein the one or more other therapeutic agents are selected from compounds that modulate GABA activity, a GABA-B agonist, a 5-HT modulator, a melatonin agonist, an ion channel modulator, a serotonin-2 antagonist/reuptake inhibitor (SARIs), a 5-HT 6 antagonist, an orexin receptor antagonist, an H3 agonist, a noradrenergic antagonist, a galanin agonist, a CRH antagonist, human growth hormone, a growth hormone agonist, estrogen, an estrogen agonist, a neurokinin-1 drug; and antipsychotic agents; in free or pharmaceutically acceptable salt form.
12. The method according to claim 10 , wherein the one or more other therapeutic agents are antipsychotic agents selected from chlorpromazine, haloperidol, droperidol, fluphenazine, loxapine, mesoridazine molindone, perphenazine, pimozide, prochlorperazine promazine, thioridazine, thiothixene, trifluoperazine, clozapine, aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, paliperidone, asenapine, lurasidone, iloperidone, cariprazine, amisulpride, zotepine, sertindole, in free or pharmaceutically acceptable salt form.
13. The method according to claim 10 , wherein the one or more other therapeutic agents are anti-depressive agents selected from one or more of amitriptyline, amoxapine, bupropion, citalopram, clomipramine, desipramine, doxepin, duloxetine, escitalopram, fluoxetine, fluvoxamine, imipramine, isocarboxazid, maprotiline, mirtazapine, nefazodone, nortriptyline, paroxetine, phenelazine sulfate, protriptyline, sertraline, tranylcypromine, trazodone, trimipramine, and venlafaxine.
14. The method according to claim 10 , wherein the one or more other therapeutic agents are anti-depressive agent selected from selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and tricyclic antidepressants.
15. The method according to claim 14 , wherein the anti-depressive agent is an SSRI.
16. The method according to claim 8 , wherein said dementia is selected from mild cognition impairment, senile dementia, Alzheimer's disease, Pick's disease, fronto-temporal dementia, parasupranuclear palsy, dementia with Lewy bodies, vascular dementia, Huntington's disease, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, elderly depression, Wernicke-Korsakoffs syndrome, cortico-basal degenerations and prion disease, autism, or attention deficit hyperactivity disorder.
17. The method according to claim 6 , wherein the central nervous system disorder is residual phase symptoms of schizophrenia, delusional disorder, major depression with psychosis, bipolar disorder with psychotic symptoms, brief psychotic disorder, schizophreniform disorder, schizoaffective disorder or psychosis caused by a medical condition or substance use;
wherein the residual phase symptoms are selected from blunted affect, emotional withdrawal, poor rapport, passive or apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking; somatic concern, anxiety, guilt feelings, tension, mannerisms and posturing, depression, motor retardation, uncooperativeness, unusual thought content, disorientation, poor attention, lack of judgment and insight, disturbance of volition, poor impulse control, preoccupation and active social avoidance; cognitive impairment, and sleep disorders.
18. The method according to claim 17 , wherein the central nervous system disorder is residual symptoms of schizophrenia.
19. The compound according to claim 1 , wherein the compound has greater than 90% incorporation of deuterium at the indicated deuterium positions of the structure.
20. The compound according to claim 1 , wherein the compound has greater than 97% incorporation of deuterium, at the indicated deuterium positions of the structure.
21. The composition according to claim 5 , wherein the compound is the compound of Formula II.
22. The compound according to claim 3 , wherein the compound is the compound of Formula II.
23. The compound according to claim 20 , wherein the compound is the compound of Formula II.